Skip to main content

Modulators of Multidrug Resistance Proteins in the Management of Anticancer and Antimicrobial Drug Resistance and the Treatment of Inflammatory Diseases

Buy Article:

$55.00 plus tax (Refund Policy)

Human multidrug resistance protein (MRP/ABCC) family contains 9 members (MRP1-9) which transport a structurally diverse array of anticancer and antimicrobial drugs and several important endogenous substances including prostaglandins (PGs) and leukotrienes (LTs) with different substrate specificity. MRP1-5 can collectively confer resistance to natural product anticancer drugs and their conjugated metabolites, platinum compounds, folate antimetabolites, nucleoside and nucleotide analogs, and alkylating agents. MRP1-3 are often associated with tumor resistance which is often caused by an increased efflux and decreased intracellular accumulation of natural product anticancer drugs and other anticancer agents. Both PGE1 and PGE2 are known high-affinity substrates of MRP4, but not MRP1, MRP2, MRP3 and MRP5. LTC4 is a substrate of MRP1, MRP2, MRP3, and MRP6-8. MRP2 is also able to transport LTD4 and LTE4. Experimental studies in Abcc1-defficient mice have demonstrated a role of MRP1 in inflammation process in vivo. Abcc3- deficcient mice have normal bile salt transport, however, they have decreased blood bilirubin glucuronide levels. Abcc6- deficient mice show remarkable mineralization of the connective tissues, including skin, arterial blood vessels, and retina. Most MRP/ABCC transporters are subject to inhibition by a variety of compounds. Drug targeting of these transporters to overcome MRP/ABCC-mediated multidrug resistance may play a role in cancer and infection (e.g. HIV infection) chemotherapy. Some modulators of MRPs have shown reversing effects on MDR phenotype in preliminary clinical studies and some modulators of MRPs may modify the inflammatory process and consequently ameliorate the inflammatory symptoms. A better understanding of the interactions of these modulators with MRPs has important implications in development of novel drugs for treatment of cancer, infection and inflammation.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: ATP-binding cassette (ABC); Abacavir; Acemetacin; Anthracyclines; Anti-HIV Agents; Antiviral Agents; Benzbromarone; Bilirubin-glucuronide secretion; Camptothecins; Cancer; Cefalotin; Cefazolin; Cefepime; Cefmetazole; Cefoperazone; Cefotaxime; Cefsulodin; Ceftizoxime; Chemotherapy; Daunorubicin; Didanosine; Doxorubicin; Emtricitabine; Epipodophyllotoxins; Glutathione; Heterooctameric transmembrane complexes; Hyperinsulinemic hypoglycemia; Inflammatory diseases; Irinotecan; Lamivudine; Leukotrienes (LTs); MRP; Multidrug Resistance Proteins; Nucleotide-binding domain; Probenecid; Prostaglandins (PGs); Stavudine; Sulfinpyrazone; Sulfonylurea receptors; Tenofovir; Thromboxane (TX); Transmembrane domains; Vinblastine; Vincristine; Zidovudine; chemotherapy; drug resistance; inflammatory disease; inhibitor; substrate

Document Type: Research Article

Affiliations: School of Health Sciences & Health Innovations Research Institute (HIRi), RMIT University, Bundoora,Victoria 3083, Australia.

Publication date: 2010-12-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more